BioTrinity 2013 can already count over 90 investor delegates from nearly 80 investment firms attending (still rising!) as well as a number of individual Angel investors also attending. We are also delighted that corporate venture fund involvement at BioTrinity has continued to grow!  The new trend which began last year continues: a number of investor firms are sending more than one delegate, increasing the chance of you getting that all important meeting.  This year again, we monitor the quality of investment firms which we allow to participate, which we continue to improve year-on-year.

Investment Firms already confirmed as participating in 2013:

• AbbVie Biotech Ventures (USA)
• Abingworth Management (UK)
• Advent Life Sciences (UK)
• Akesios Associates (UK)
• Albion Ventures (UK)
• Alida Capital International (UK)
• Amorepacific Ventures (South Korea)
• Andy Richards (UK)
• Aquarius Equity Partners (UK)
• Arthurian Life Sciences (UK)
• Boehringer Ingelheim Venture Fund (Germany)
• Burrill & Company (Switzerland)
• Cambridge Enterprise (UK)
• Celtic Pharma Holdings Advisors LLP (UK)
• Clubb Capital (UK)
• Delta Partners (Ireland)
• DFJ Esprit LLP (UK)
• Edison Group (UK)
• Edmond de Rothschild Investment Partners (France)
• Entrepreneurs Fund (UK)
• Epiphany Capital (UK)
• Esperante Ventures (Netherlands)
• Finance Wales (UK)
• Forbion Capital Partners (Netherlands and Germany)
• Fountain Healthcare Partners (Ireland)
• Imperial Innovations (UK)
• Index Ventures (UK)
• Inventages (UK)
• IP Group plc (UK)
• Karolinska Development (Sweden)
• Kreos Capital (UK)
• Kurma Life Sciences Partners (UK/France)
• Longwall Ventures Partners ECF (UK)
• Longbow Capital LLP (UK)
• Lundbeckfond Ventures (Denmark)
• Mann Bioinvest (Isle of Man)
• Medimmune Ventures (USA)
• Mercia Fund Management (UK)
• Midven (UK)
• Mitsui & Co. Global Investment (USA)
• MP Healthcare Venture Management, Inc. (USA)
• MVM Life Science Partners LLP (UK)
• NeoMed (Switzerland)
• New Hill Management (UK)
• Nomura Code (UK)
• Norgine Venture Investments (UK)
• Novartis Venture Fund (Switzerland)
• Novo A/S (Denmark)
• Novo Seeds (Denmark)
• Octopus Investments (UK)
• OSEM (UK)
• Parkwalk Advisors (UK)
• Paul Capital (UK)
• Peel Hunt (UK)
• Phase4 Ventures (UK)
• Rainbow Seed Fund 
• Rock Spring Ventures (UK)
• Science-to-Market GmbH (Germany)
• Seroba Kernel (Ireland)
• Seventure Partners (France)
• Shire Strategic Investments (USA)
• Silicon Valley Bank (UK)
• Sofinnova Partners (France)
• SR One (UK)
• STJ Advisors (UK)
• SV Life Sciences Advisers LLP (UK)
• Syncona Partners (UK)
• Takeda Ventures, Inc. (USA)
• Technology Strategy Board (UK)
• The Royal Society Enterprise Fund (UK)
• TPG Biotech (UK)
• TVM Capital GmbH (Germany)
• Ventac Partners (Spain)
• Wellington Partners (Germany)
• WG Partners (UK)
• Ysios Capital Partners (Spain)
• Zoticon BioVentures (Israel)

Investment Firms which participated in 2012:

• 3i Group
• Abbott Biotech Ventures (USA)
• Abingworth LLP
• Advent Venture Partners
• Aescap Venture (Netherlands)
• Albion Income and Growth VCT plc
• Albion Ventures LLP
• Apposite Capital
• Aquarius Equity Partners
• Astellas Venture Management
• Atlas Venture (USA)
• Beer and Partners Ltd
• Boehringer Ingelheim Venture Fund (Germany)
• Celtic Pharma Holdings Advisors LLP
• Crédit Agricole Private Equity (France)
• Clubb Capital
• Delta Partners (Ireland)
• ECI Partners
• EdRIP (France)
• Entrepreneurs Fund Management LLP
• Esperante Ventures (Netherlands)
• Finance Wales
• Forbion Capital Partners (Netherlands)
• Fountain Healthcare Partners (Ireland)
• Genetrix SL (Spain)
• Imperial Innovations
• Index Ventures
• Inventages
• IP Asset Ventures
  
• IP Group plc
• JP Morgan Asset Management
• Karolinska Development AB (Sweden)
• KLS-Partners (France)
• Lundbeckfond Ventures (Denmark)
• Mann Bioinvest (Isle of Man)
• MedImmune Ventures (USA)
• Mercia Fund Management
• Merck Research Venture Fund (USA)
• Merck Serono Ventures (Switzerland)
• Midven Ventures
• MVM Life Science Partners LLP
• NeoMed (Switzerland)
• New Hill Management
• Nextech Invest (Switzerland)
• Nomura Code
• Novo A/S (Denmark)
• Oxford Capital Partners
• Oxford Technology Management
• Paul Capital
  
• Phase4 Ventures
• Private Investors
• Rainbow Seed Fund
• Science to Market Venture Capital GmbH (Germany)
  
• Seroba Kernel Life Sciences (Ireland)
• Seventure Partners (France)
• Shire Strategic Investment Group (USA)
• Silicon Valley Bank
• Singer Capital Markets
• Sofinnova Ventures (France)
• SPARK Impact
• SPARK Ventures
• SR One Limited
• SV Life Sciences
• Synergis Technologies
• Team Ventures
• Technology Strategy Board
  
• The FSE Group
  
• The Wellcome Trust
• TPG Capital LLP
• Wellington Partners (Germany)
• Ysios Capital Partners (Spain)